Lead Product(s): Antisense oligonucleotide therapies
Therapeutic Area: Cardiology/Vascular Diseases
Highest Development Status: Undisclosed Product Type: Large molecule
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition March 23, 2020
Under this agreement, Lipigon acquires certain antisense drug candidates, which were developed with Secarna's proprietary LNAplusTM platform, including the corresponding patent portfolio.